ZEVRA THERAPEUTICS (ZVRA) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
ZEVRA THERAPEUTICS insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 6 sold $2.5M of ZVRA stock on the open market.
Get emailed when insiders cluster-buy stocks like ZVRA
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
ZVRA insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $613K | 2 |
| Q2 2026 | — | 0 | $458K | 2 |
| Q1 2026 | — | 0 | $1.2M | 8 |
| Q4 2025 | — | 0 | $211K | 1 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 ZEVRA THERAPEUTICS, INC. insiders reported open-market purchases totaling $0, while 6 insiders reported sales totaling $2.5M. 12 of 13 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Aug 17SEC | Rahsaan ThompsonGeneral Counsel | Sell Plan | 42,66637,569 held (−53%) | $11.13 | $475K | +2.3% | — |
| Aug 12SEC | Corey Michael WattonDirector | Sell | 12,3001,800 held (−87%) | $11.25 | $138K | +1.2% | — |
| Jun 23SEC | Rahsaan ThompsonGeneral Counsel | Sell Plan | 34,55780,235 held (−30%) | $12.68 | $438K | -10.2% | — |
| May 13SEC | Rahsaan ThompsonGeneral Counsel | Sell Plan | 1,79448,125 held (−4%) | $11.30 | $20K | +0.8% | — |
| Feb 10SEC | Neil F. McfarlaneCEO, President | Sell Plan | 14,625387,225 held (−4%) | $8.56 | $125K | +33.1% | — |
| Feb 4SEC | Joshua SchaferCco | Sell Plan | 10,50062,278 held (−14%) | $9.19 | $96K | +23.9% | — |
| Feb 4SEC | Timothy J. SangiovanniSvp, Finance & Corp Controller | Sell Plan | 3,00029,590 held (−9%) | $9.18 | $28K | +24.1% | — |
| Feb 2SEC | Neil F. McfarlaneCEO, President | Sell Plan | 91,000364,350 held (−20%) | $9.38 | $854K | +21.4% | — |
| Feb 2SEC | Adrian W QuartelChief Medical Officer | Sell Plan | 4,5339,723 held (−32%) | $8.83 | $40K | +29.0% | — |
| Feb 2SEC | Rahsaan ThompsonGeneral Counsel | Sell Plan | 4,08049,919 held (−8%) | $8.83 | $36K | +29.0% | — |
| Feb 2SEC | Joshua SchaferCco | Sell Plan | 3,37537,444 held (−8%) | $8.83 | $30K | +29.0% | — |
| Feb 2SEC | Timothy J. SangiovanniSvp, Finance & Corp Controller | Sell Plan | 1,75020,924 held (−8%) | $8.82 | $15K | +29.1% | — |
| Oct 10SEC | Neil F. McfarlaneCEO, President | Sell Plan | 19,500222,016 held (−8%) | $10.82 | $211K | +5.3% | — |
Insiders at ZEVRA THERAPEUTICS, INC.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Neil F. McfarlaneCEO, President | — | $1.2M | Feb 10, 2026 | — |
| Rahsaan ThompsonGeneral Counsel | — | $969K | Aug 17, 2026 | — |
| Corey Michael WattonDirector | — | $138K | Aug 12, 2026 | — |
| Joshua SchaferCco | — | $126K | Feb 4, 2026 | — |
| Timothy J. SangiovanniSvp, Finance & Corp Controller | — | $43K | Feb 4, 2026 | — |
| Adrian W QuartelChief Medical Officer | — | $40K | Feb 2, 2026 | — |
ZVRA stock: common questions
Are ZEVRA THERAPEUTICS, INC. insiders buying ZVRA stock?
In the past 12 months, 0 insiders reported open-market purchases of ZVRA worth $0.
Are ZEVRA THERAPEUTICS, INC. insiders selling ZVRA stock?
6 insiders reported sales worth $2.5M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ZVRA's 52-week range?
Over the past year ZVRA has traded between $8.10 and $14.75. It last closed at $11.39 on Oct 9, 2026.